Estrigenix Therapeutics Raises $2M to Advance Selective Estrogen Therapy
- Category
- · Funding · Global
- Date
- July 22, 2026
- Source
- Femtech Insider
Summary
Estrigenix Therapeutics secured the first close of a $2 million Series Seed led by Talents Fund I to advance its selective estrogen receptor-beta (ERβ) platform through preclinical development. Unlike conventional hormone therapy, the biotech company is developing a selective, non-steroidal therapy designed to activate estrogen-receptor beta (ERβ) while avoiding estrogen receptor-alpha (ERα), which is associated with risks of traditional treatments. Estrigenix’s approach… The post Estrigenix Therapeutics Raises $2M to Advance Selective Estrogen Therapy first appeared on .
The company sits inside the Therapeutics and Digital Health/Telehealth lane of the women's health map at Seed ($2M). Track it against comparable rounds to see whether pricing in this lane is holding.
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- Femtech Insider Primary source